Professor Treon speaking to delegates of the 79th Annual Meeting of the Japanese Society of Hematology.

One hundred and fifty delegates to the 79th Annual Meeting of the Japanese Society of Hematology attended a workshop on Waldenstrom’s Macroglobulinemia, which featured Dr. Steve Treon, Professor of Medicine at Harvard Medical School and Director of the Bing Center for WM at the Dana Farber Cancer Institute.


The workshop which was held on Friday, October 20, 2017 was entitled “Genomic and Treatment Advances in Waldenstrom’s Macroglobulinemia”, and provided an update on findings made possible by whole genome sequencing of WM, including mutations in MYD88 and CXCR4, and their impact on treatment decision making for WM. Dr. Treon discussed current rituximab based therapies, including the use of bendamustine and proteasome inhibitors, and the role of ibrutinib in the treatment of WM. The session was chaired by Dr. Michihide Tokuhira, of the Department of Hematology, at Saitama Medical Center, Saitama Medical University.